(Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. (“Yerbae”) after ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United ...

Mirdametinib is approved in the U.S. for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) ...

GN Store Nord A/S hereby announces that on May 22, 2025, pursuant to Section 38 (1) and Section 39 (1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ...

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Outlook Therapeutics are expected to be approximately $13.0 million.

AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 ...

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité ...

Le 19 mai 2025, la Société a reçu l’autorisation des autorités administratives compétentes (DREETS) de mettre en œuvre le plan de réorganisation stratégique des activités qui a été présenté aux ...

AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce aujourd'hui le règlement-livraison de son augmentation de capital annoncée le 20 mai 2025 d’un montant de 1,8 ...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents.